Skip to main content

Research News

academics

 

Clinical research courses

  • Dissolving cardiac device monitors, treats heart disease

    Nearly 700,000 people in the United States die from heart disease every year, and one-third of those deaths result from complications in the first weeks or months following a traumatic heart-related event.

  • Study Sets New Standard for Graft-Versus-Host Disease Prevention After Stem Cell Transplant

    Clinicians have a new standard for graft-versus-host disease (GVHD) prevention after allogeneic hematopoietic stem cell transplantation, according to results from a phase III study published June 22 in the New England Journal of Medicine. The new standard is more effective at preventing GVHD and came with less side effects, compared with the current gold standard.

  • Drug decelerates bacterial race to antibiotic resistance

    A team of researchers at Baylor College of Medicine is gaining ground in their search for solutions to the global problem of bacterial antibiotic resistance, which was responsible for nearly 1.3 million deaths in 2019.

  • Belize certified malaria-free by WHO

    The World Health Organization (WHO) has certified Belize as malaria-free, following the country’s over 70 years of continued efforts to stamp out the disease.

    “WHO congratulates the people and government of Belize and their network of global and local partners for this achievement”, said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Belize is another example of how, with the right tools and the right approach, we can dream of a malaria-free future.”

  • Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology

    The Department of Biotechnology (DBT) has announced that the Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology by Gennova Biopharmaceuticals Ltd. and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC), has got a nod from the office of the Drug Control General of India (DCGI) for Emergency Use Authorization (EUA).

  • Scientists identified an over-the-counter antihistamine as a treatment for multiple sclerosis

    A decade after UC San Francisco scientists identified an over-the-counter antihistamine as a treatment for multiple sclerosis, researchers have developed an approach to measure the drug’s effectiveness in repairing the brain, making it possible to also assess future therapies for the devastating disorder.

  • New Discovery Can Help Detect Brain Tumours

    Folate-based radiopharmaceuticals can be used in positron emission tomography (PET) imaging to detect folate receptors in brain tumours. The discovery of folate receptors and their exploitation potential with respect to brain tumours is a new and significant finding in the field.

  • DNA architecture could be used to regulate cancer progression

    Cancer is caused by changes in DNA sequences (genes) and subsequently, the function of their end product, proteins. In a recent study, a team of researchers proposed to use the architecture of a specific DNA to control the synthesis of the protein factor, as to regulate the progression of some cancers, especially lung, breast, and glioblastoma (brain tumour).

  • A lung injury therapy derived from adult skin cells

    Therapeutic nanocarriers engineered from adult skin cells can curb inflammation and tissue injury in damaged mouse lungs, new research shows, hinting at the promise of a treatment for lungs severely injured by infection or trauma.

    Researchers conducted experiments in cell cultures and mice to demonstrate the therapeutic potential of these nanoparticles, which are extracellular vesicles similar to the ones circulating in humans’ bloodstream and biological fluids that carry messages between cells.

  • Parkinsons disease drug Ropinirole safely slowed the progression of ALS for over 6 months in a clinical trial

    Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles. There is no cure, and current treatments focus on reducing symptoms and providing supportive care. Reporting June 1 in the journal Cell Stem Cell, researchers from Japan show in an early clinical trial that the Parkinson's disease drug ropinirole is safe to use in ALS patients and delayed disease progression by 27.9 weeks on average.

Subscribe to Research News